Novavax’s Covid shot is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans \u2014 but analysts aren’t worried about\u2026
Novavax's updated Covid vaccine is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans — but analysts aren't worried about that delay.
Public health officials see Novavax's vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna, which teach cells how to make proteins that trigger an immune response against Covid. Novavax's shot fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles.
Still, Mamtani said the authorization label for Novavax's new vaccine is"broad and without any notable restrictions for the first time," which will likely make the shot as widely accessible to teens and adults as the new mRNA jabs. That puts Novavax on more of a level playing field with Pfizer and Moderna this fall, even as a late entrant to the game.for Novavax's last Covid booster was far more restrictive.
There's no way of knowing whether the rollout of Novavax's new shot will see similar logistical snags or if it will have a smoother launch. The federal governmentdistribution and coverage to the private market for the first time this fall. That has proved to be a tricky transition for the U.S. health-care system.A sign advertises COVID-19 vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, August 14, 2023.
"During the first season of Covid, everyone rushed to get vaccinations because it was really an emergency state. But now people have a mindset where they're saying, 'OK, I will wait and see how bad Covid really gets,'" Song said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novavax touts non\u002DmRNA COVID\u002D19 vaccine, hopeful to meet domestic production deadlineThe new formulation is awaiting Health Canada approval.
Baca lebih lajut »
Change Makers: Moderna's Stéphane Bancel on Passion, Advancing mRNA, Cancer, Rare Diseases, and COVID-19The CEO of Moderna speaks with WebMD CMO John Whyte, MD, MPH, about the potential of mRNA technology and much more.
Baca lebih lajut »
In Early Trial, Promising Results for Moderna's Combo COVID-Flu VaccineModerna Inc. announced Wednesday that it has seen positive early results with a new vaccine that would guard against four strains of flu plus COVID-19.
Baca lebih lajut »
Moderna moving to late-stage trial on COVID-flu combo vaccineA combined shot could simplify immunizations while simultaneously fighting two respiratory diseases that require repeated vaccinations.
Baca lebih lajut »
Evolve and Pfizer cutting workers in Denver and BoulderDenver-based Evolve is letting go of another 175 workers just four months after it dismissed 164 workers in response to a big drop-off in the vacation home rental market.
Baca lebih lajut »